Latest 2024 PCa-related GuCS Meeting Coverage from MedPage Today:
More Evidence That ARSIs for Prostate Cancer Differ in Cognitive Effects -More fatigue, depression, worse reaction time with enzalutamide as compared with abiraterone, January 29, 2024:
Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testing: Multiparametric Stockholm3 avoided far more unnecessary biopsies without sacrificing sensitivity, January 28, 2024:
Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - Combination improved PFS versus more hormonal therapy, but control arm questioned, January 26, 2024:
Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone - In small first-line trial, PFS more than doubled with combination, January 26, 2024:
Study Supports High-Dose RT, Long-Term ADT as Standard for High-Risk Prostate Cancer - OS, PFS, cancer-specific survival all improved, with no increase in toxicity, January 26, 2024:
Thanks for posting this information... glad I was put on Abi from the get go, but the ADT drugs are packed with side effects..
Good to see the MCRPC folks get some more treatment options... science knowledge adding to increased OS...precision medicine...and improved diagnosis with less unnecessary biopsies...
The Stockholm 3 test may have saved my life. Previously , PSA had to be above 3 to result in further testing. Now 1.5 became the cut-off. I had 1.7 and subsequent testing showed high-risk metastized cancer.
P-B - Very good to hear! Based on my personal experience and that of extended family members with PCa, I've come to feel that PSA needs to be evaluated in context; i.e., relative to age, BMI (or equivalent measure), free-to-total PSA, in relation to T (free & total), and prostate size (BPH issues initially - actual prostate size from MRI or ultrasound is better), and PSA velocity/doubling time. Sans that sort of context granularity, it can often be a poor indicator of PCa risk.
Your example proves the point, and hopefully the newer testing methods will find their way into wide use by urologists and PCPs in annual exams and yearly monitoring for high-risk patients.
doing my own genetics through 23andme before they watered it down and before i was diagnosed help me identify a very deleterious FGFR4 mutation predicting 6x chance of aggressive prostate cancer and 5x chance of it becoming metatastic .
KocoPr, You are another example of patient advocacy paying dividends. I'm doing out-of-pocket walk-in-lab monitoring (that my cancer center deems unnecessary) for similar reasons. Seems to me that male hormone panels and genetic-risk profiling should now be routine for all men - starting at the time they are first suspected to be at-risk for PCa, if not before.
Precision medicine requires detailed data to be precise. Right now we are still mostly using treatment paradigms from over 40 years ago - with newer treatment avenues (like PSMA theranostics & BAT) only available to those who are CR and heavily treated. Change maybe coming, but many of us will be long gone before it gets here.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Efficacy and safety of BAT in CRPC following Abi or Enza resistance: A systematic review
Combine standard care with alternative care
Dose titration for CRPC 
